Maytansine CAS 35846-53-8: Potent Cytotoxic Agent for Advanced Cancer Therapies and Antibody-Drug Conjugates
Discover the critical role of Maytansine (CAS 35846-53-8) as a leading cytotoxic payload in cutting-edge Antibody-Drug Conjugates (ADCs), revolutionizing targeted cancer therapy.
Get a Quote & SampleProduct Core Value
Maytansine
Maytansine, identified by CAS 35846-53-8, is a highly potent microtubule-targeting compound that induces mitotic arrest and effectively kills cancer cells at extremely low concentrations. While its direct application as a standalone anticancer agent was limited by systemic toxicity and lack of tumor specificity, its exceptional cytotoxicity makes it an ideal payload for Antibody-Drug Conjugates (ADCs). As a reliable supplier in China, we provide high-quality Maytansine derivatives essential for developing next-generation cancer treatments.
- Explore the mechanism of action for Maytansine, a potent microtubule-targeting anticancer drug, in disrupting cell division.
- Learn how Antibody-Drug Conjugate Payload DM1 and DM4 leverage Maytansine's potency for targeted cancer therapy.
- Understand the significance of Maytansine CAS 35846-53-8 in the development of advanced pharmaceutical intermediates.
- Investigate the benefits of utilizing this cytotoxic agent in targeted drug delivery systems for enhanced efficacy.
Advantages of Using Maytansine
Enhanced Targeted Delivery
Maytansine derivatives, when conjugated to antibodies, facilitate targeted cancer therapy, concentrating potent cytotoxic effects directly on tumor cells, a key aspect of Antibody-Drug Conjugate Payload DM1 and DM4.
Potent Cytotoxicity
The remarkable potency of Maytansine makes it an exceptionally effective cytotoxic agent, capable of eliminating cancer cells at subnanomolar concentrations, crucial for advancing targeted cancer therapy.
Reduced Systemic Toxicity
By enabling targeted delivery, Maytansine as an ADC payload significantly reduces the systemic exposure and associated toxicities compared to traditional chemotherapy, improving patient outcomes in targeted drug delivery.
Key Applications
Antibody-Drug Conjugates (ADCs)
Maytansine and its analogs like DM1 and DM4 are the cornerstone payloads for numerous ADCs, offering a potent mechanism to target and eliminate cancer cells selectively.
Pharmaceutical Intermediates
As a crucial pharmaceutical intermediate, Maytansine CAS 35846-53-8 is vital for the synthesis of complex therapeutic agents, supporting the development of new cancer drugs.
Targeted Cancer Therapy
The targeted cancer therapy approach, utilizing Maytansine's cytotoxic power through antibody conjugation, represents a significant advancement in treating various forms of cancer.
Drug Development Research
Maytansine is integral to ongoing drug development research, particularly in exploring new mechanisms and combinations for improved efficacy in targeted drug delivery.